Severe Outcomes in Suspected Pediatric Delta-8-THC Exposures DOI
Simon J. Ostrowski, Matthew C. Scanlon, David J. Barton

et al.

Journal of Medical Toxicology, Journal Year: 2024, Volume and Issue: 21(1), P. 89 - 92

Published: Dec. 24, 2024

Language: Английский

The Resurgence of Synthetic Cannabinoid Receptor Agonists as Adulterants in the Era of Cannabis Legalization: Lessons from Prior Epidemics and Clinical Implications DOI
Aaron P. Jones, Ali S. Taha, Grover P. Miller

et al.

Neuroscience & Biobehavioral Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 106043 - 106043

Published: Feb. 1, 2025

Language: Английский

Citations

1
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America’s Poison Centers DOI

Alice Burgess,

Hannah L. Hays, Jaahnavi Badeti

et al.

Clinical Toxicology, Journal Year: 2024, Volume and Issue: 62(4), P. 256 - 266

Published: April 2, 2024

Since the passage of Farm Bill in 2018, availability synthetic tetrahydrocannabinols has increased, including delta-8 tetrahydrocannabinol, delta-10 and tetrahydrocannabinol-O acetate. The objective this study is to investigate characteristics acetate exposures reported United States poison centers from 2021 2022.

Language: Английский

Citations

5
Rapid analysis of Δ8-tetrahydrocannabinol, Δ9-tetrahydrocannabinol, and Cannabidiol in Δ8-tetrahydrocannabinol edibles by ag(I) paper spray mass spectrometry after simple extraction DOI Creative Commons
Si Huang, Teris A. van Beek,

Erik Beij

et al.

Food Chemistry, Journal Year: 2025, Volume and Issue: 479, P. 143829 - 143829

Published: March 11, 2025

Language: Английский

Citations

0
Identification of Acetyl, Propionyl, and Butanoyl Derivatives of THC and Its Analogs, and Their Synthetic By‐Products in Oils and a Herbal Product DOI Open Access
Rie Tanaka,

Michiho Ito,

Ruri Kikura‐Hanajiri

et al.

Drug Testing and Analysis, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

ABSTRACT Since 2021, products claiming to contain Δ 9 ‐tetrahydrocannabinol (Δ ‐THC) analogs have been distributed online and in physical stores, including liquid cartridges for electronic cigarettes, herbal products, gummy products. This study identified the ingredients THC online. Seven oil one product were analyzed via gas chromatography–mass spectrometry (GC–MS) chromatography–photodiode array–mass (LC–PDA–MS). After isolating purifying unknown components from structural analysis was performed by measuring 1 H 13 C nuclear magnetic resonance (NMR) spectroscopy various two‐dimensional NMR (COSY, HMQC, HMBC, NOESY). The revealed presence of 8 acetate ‐THC‐O), 4(8) ‐ iso ‐THC‐ O ‐acetate, ‐tetrahydrocannabihexol ‐THCH‐O), ‐tetrahydrocannabiphorol ‐THCP‐O), ‐propionate, ‐THCB‐ ‐butanoate, ‐THCP‐ ‐butanoate these

Language: Английский

Citations

0
A Within-Subject Cross-Over Trial Comparing the Acute Effects of Oral Delta-8-Tetrahydrocannabinol and Delta-9-Tetrahydrocannabinol in Healthy Adults DOI
C. Austin Zamarripa, Tory R. Spindle,

Destiny Schriefer

et al.

Drug and Alcohol Dependence, Journal Year: 2025, Volume and Issue: unknown, P. 112676 - 112676

Published: April 1, 2025

Language: Английский

Citations

0
Hemp-derived tetrahydrocannabinol (THC) and kratom related health claims provided by smoke shop employees: a secret shopper study DOI
Kirk E. Evoy,

Sujata Acharya,

Michael Bloomfield

et al.

The American Journal of Drug and Alcohol Abuse, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 9

Published: May 22, 2025

Background: US smoke shop prevalence is growing and stores are diversifying products beyond nicotine vape supplies, often selling non-regulated psychoactive substances.Objectives: Investigate health claims safety information provided by employees regarding hemp-derived tetrahydrocannabinol (THC) kratom.Methods: Secret shopper visits were conducted at 100 San Antonio Austin, Texas shops. Using scripted questions, shoppers assessed whether the sold THC kratom, what these could be used for, adverse effects. Shoppers documented product availability, disease states referenced, made, effects mentioned, guidance for use related to pregnancy. Descriptive statistics calculated characterize reports.Results: (100%) kratom (94%) routinely stocked Most made least one claim (50%) or (81%). Claims pain (50%), insomnia (31%), mental disorders (27%) most commonly discussed THC, while drug withdrawal/cravings (76%), (69%), conditions (31%) frequent kratom. When specifically asked about effects, 22% 24% of employees, respectively, did not disclose any risks kratom; others minimal information. The common sedation (36%) psychiatric dependence (59%) gastrointestinal (24%) kratom.Conclusion: Efforts develop evidence-based consumer improve incentivize store owners devote resources employee education needed.

Language: Английский

Citations

0
Prevalence of cannabidiol use and correlates in U.S. adults DOI Creative Commons
Namkee G. Choi,

C. Nathan Marti,

Bryan Y. Choi

et al.

Drug and Alcohol Dependence Reports, Journal Year: 2024, Volume and Issue: 13, P. 100289 - 100289

Published: Oct. 9, 2024

Cannabidiol (CBD) use has been increasing for its putative therapeutic potential various health conditions. Research using a nationally representative sample is needed to examine characteristics of CBD users. Data came from the adult (N=47,100) 2022 U.S. National Survey on Drug Use and Health. We fitted generalized linear models sociodemographic, health, other substance use, cannabis risk perception as correlates CBD-only CBD-cannabis co-use, compared cannabis-only use. In 2022, 20.6 % 23.0 adults reported cannabis, respectively, in preceding 12 months, 63 users also used cannabis. was significantly higher among women (CBD-only vs. use: IRR=1.43, 95 CI=1.31-1.57), but lower Black Hispanic individuals non-Hispanic White IRR=0.71, CI=0.60-0.85 individuals; IRR=0.79, CI=0.65-0.96 individuals). Older ages, SES, chronic medical conditions, mental illness, high were associated with likelihood versus co-users at most terms disorder, problems. The prevalence self-reported those physical problems warrants public warnings about side effects drug interactions. co-use rate calls more research benefits negative co-use.

Language: Английский

Citations

3
The Public Health Challenge of Δ8-THC and Derived Psychoactive Cannabis Products DOI

Jennifer M. Whitehill,

Kelly E. Dunn,

Reneé M. Johnson

et al.

JAMA, Journal Year: 2024, Volume and Issue: 331(10), P. 834 - 834

Published: March 12, 2024

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

Citations

2
Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report DOI Creative Commons

Varun Rawal,

Matthew Gallardo, Katelyn Henderson

et al.

Journal of Addictive Diseases, Journal Year: 2023, Volume and Issue: 43(1), P. 98 - 103

Published: Dec. 14, 2023

Introduction Tianeptine is a tricyclic antidepressant (TCA) without FDA-approval that acts on dopamine and norepinephrine. It has opioid agonist activity increasingly being used for recreational purposes to achieve an opioid-like anxiolytic effect. This can lead clinical addiction with subsequent withdrawal symptoms resembling of withdrawal. There are limited cases detailing the management tianeptine

Language: Английский

Citations

3
Asystole in a young child with tetrahydrocannabinol overdose: a case report and review of literature DOI Creative Commons

Mats Steffi Jennifer Masilamani,

Rebecca Leff, Yu Kawai

et al.

Frontiers in Toxicology, Journal Year: 2024, Volume and Issue: 6

Published: May 9, 2024

Introduction The association between Δ8-tetrahydrocannabinol (THC) and cardiac dysrhythmia has not been well described in children. Asystole, while consistent with reports of severe bradycardia apnea children, is uncommonly the current literature. We present first pediatric case asystole following THC ingestion. Case A 7-year-old male presented to emergency department (ED) after his mother noticed he was lethargic 3–4 h accidental ingestion five 15 mg (total 75 mg) Δ8-THC gummies. Upon arrival, vitally stable well-appearing. He received maintenance intravenous fluids. Approximately 7 initial ingestion, experienced a >15-s episode on telemetry requiring sternal rub awaken. This followed by (60 beats per minute range) which resolved 0.1 glycopyrrolate. admitted PICU, drowsy but arousable vitals. After an uneventful 24-h (post-ingestion) PICU observation, discharged home condition. Discussion To our knowledge, this reported THC-induced asystole. etiology may be attributed direct vagal stimulation or respiratory depression. typical recommended observation time potential toxicity 3–6 children have returned their physiological behavioral baseline. Our patient clinically no concern for depression yet asystolic pause Conclusion demonstrates that occur patients large ingestions those symptoms can appear late outside currently period.

Language: Английский

Citations

0